Karyopharm Therapeutics (NASDAQ:KPTI) Releases Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) issued its quarterly earnings results on Thursday. The company reported ($2.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.03, Zacks reports. The business had revenue of $34.08 million during the quarter, compared to the consensus estimate of $33.16 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Phase 3 myelofibrosis readout in March 2026: Karyopharm expects top-line data from its frontline selinexor + ruxolitinib (CENTURY/SENTRI) trial next month, positioning the combo to be the first frontline combination and a potential major value driver if positive.
• Phase 3 endometrial cancer data mid‑2026: The EXPORT‑EC042 trial remains on track for mid‑2026 top‑line results, supported by promising long‑term SIENNA subgroup data in P53 wild‑type/pMMR patients that Karyopharm highlights as a meaningful expansion opportunity.
• Near‑term cash runway into Q2 2026: The company ended 2025 with ~$64.1M in cash and says existing liquidity funds operations only into the second quarter, and it is actively evaluating financing and strategic options to bridge to and beyond upcoming readouts.
• Commercial performance and 2026 guidance: Xpovio net product revenue grew to $114.9M in 2025, management expects $115M–$130M in 2026 and continues to position Xpovio in community and peri‑T‑cell engager settings as a durable commercial foundation.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $8.98 on Friday. The company has a 50 day simple moving average of $6.93 and a 200 day simple moving average of $6.20. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.38. The firm has a market cap of $164.42 million, a PE ratio of -0.62 and a beta of 0.21.

Key Headlines Impacting Karyopharm Therapeutics

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: Company reiterated that Phase 3 readouts are on track — top‑line SENTRY (myelofibrosis) data due in March 2026 and XPORT‑EC‑042 (endometrial cancer) mid‑2026, which are meaningful binary catalysts for valuation upside. Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
• Positive Sentiment: Full‑year 2026 revenue guidance of $130M–$150M (including U.S. XPOVIO net product revenue guidance of $115M–$130M) confirms ongoing commercial sales and sets investor expectations for stable product revenue next year. This guidance provides a clearer 2026 revenue range for modeling. Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
• Neutral Sentiment: Quarterly revenue of $34.08M slightly topped consensus (~$33.16M), a modest beat that supports the company’s commercial story but is not a large surprise. Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
• Neutral Sentiment: Several short‑interest data entries in feeds show large increases but report zero shares/NaN and a 0.0 days‑to‑cover — data appears erroneous or incomplete, so treat as noise until corrected by an official short‑interest release.
• Negative Sentiment: Reported EPS figures are mixed/confusing: one provider shows a very large GAAP loss of ($5.71) that missed estimates by a wide margin, which could concern investors about one‑time charges or non‑cash items. The miss may weigh on sentiment until management clarifies the drivers. Listen to Conference Call / View Press Release

Hedge Funds Weigh In On Karyopharm Therapeutics

Several large investors have recently modified their holdings of KPTI. Geode Capital Management LLC lifted its holdings in shares of Karyopharm Therapeutics by 101.2% during the fourth quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock worth $1,382,000 after purchasing an additional 94,445 shares during the period. ADAR1 Capital Management LLC acquired a new position in Karyopharm Therapeutics during the 3rd quarter worth about $164,000. Bridgeway Capital Management LLC bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $163,000. Bank of America Corp DE grew its position in shares of Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after buying an additional 35,626 shares during the last quarter. Finally, Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at about $45,000. Institutional investors own 66.44% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on KPTI. The Goldman Sachs Group set a $12.00 target price on Karyopharm Therapeutics in a research report on Wednesday, December 17th. Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th. Piper Sandler reiterated an “overweight” rating and set a $12.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Finally, Royal Bank Of Canada cut their target price on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.83.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.